Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

September 25, 2025

FOR IMMEDIATE RELEASE

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Chairman, President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock Exchange
Contact: Naoki Kitamura, Managing Executive Officer and CFO
Telephone No.: +81-3-6279-0926

Notice Concerning Recording of Extraordinary Income Related to Sale of Non-current Assets and Shares, and Revision to Full-year Consolidated Earnings Forecast for the Fiscal Year Ending March 2026

H.U. Group Holdings, Inc. (the "Company") hereby announces that it has resolved to sale certain non-current assets and will record extraordinary income (gain on sale of non-current assets) in the third quarter of the fiscal year ending March 2026. In addition, the Company has completed the impact review of "Notice Concerning Share Transfer of Care'x." announced on September 16, 2025, and will record extraordinary income (gain on sale of shares of subsidiaries and associates) in the same period. Based on these factors, the Company has revised its full-year consolidated earnings forecast for the fiscal year ending March 2026, previously announced on May 15, 2025. Details are as follows.

1. Sale of Non-current Assets and Recording of Extraordinary Income

(1) Reason for the Sale

As announced on August 10, 2021, the Company aimed to restructure its nationwide laboratory network and acquired land in Kameoka City, Kyoto, with the intention of constructing a new Kansai laboratory to replace the existing facility of Nihon Rinsho. However, due to construction costs exceeding initial projections and in consideration of the new five-year Medium-Term Management Plan, H.U. 2030 (announced in May 2025), the Company revised its LTS business strategy to focus on optimizing laboratory functions centered on the H.U. Bioness Complex, while enhancing profitability in general testing laboratories through "selection and concentration" approach and strategic alliances. In light of these significant changes in both the business environment and strategic direction, the Company has determined that renovating existing facilities, rather than constructing a new Kansai laboratory, is the most effective way to meet testing demand. Accordingly, the Company has resolved to sale the land.

(2) Details of Assets to be Sold

Location and Area	Sale Price	Gain on Sale
Yuhigaoka 4-chome, Shinocho, Kameoka city, Kyoto (Area of Approximately 36,000 ㎡)	Approximately 4.0 billion yen	Approximately 2.3 billion yen

(3) Outline of the Purchaser

The purchaser is a domestic business corporation whose name is withheld at its request. There are no capital, personnel, or business relationships between the Company and the purchaser, and it does not classify as related party.

(4) Transaction Schedule

Date of Contract Conclusion: September 25, 2025

Date of transaction: December 2025 (scheduled)

(5) Future Outlook

As a result of the sale of the subject non-current assets, the Company will record extraordinary income of approximately 2.3 billion yen as gain on sale of non-current assets in the third quarter of the fiscal year ending March 2026. Accordingly, the full-year consolidated earnings forecast has been revised as stated in Section 3 below.

2. Sale of Shares in Care'x Inc. and Recording of Extraordinary Income

As announced on September 16, 2025, the Company resolved to sale 80% of the outstanding shares of its consolidated subsidiary, Care'x Inc. As a result, the Company will record extraordinary income of approximately 4.1 billion yen as gain on sale of shares of subsidiaries and associates in the third quarter of the fiscal year ending March 2026. Accordingly, the full-year consolidated earnings forecast has been revised as stated in Section 3 below.

3. Revision to Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 2026

(1) Full-Year Consolidated Earnings Forecast (April 1, 2025 – March 31, 2026)

	Net sales (millions of yen)	Operating profit (millions of yen)	Ordinary profit (millions of yen)	Profit attributable to owners of parent (millions of yen)	Earnings per share (yen)	(Reference) EBITDA[1] (millions of yen)
Previous Forecast (A)	252,000	8,000	6,000	5,500	96.80	30,500
Revised Forecast (B)	252,000	8,000	6,000	7,000	124.69	30,500
Change (B - A)	—	—	—	1,500	—	—
Change (%)	—	—	—	27.3	—	—
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	243,025	2,640	4,742	2,761	48.60	23,387

1.EBITDA = Operating profit + Depreciation + Amortization of goodwill

(2) Reason for Revision

As stated above, the Company has revised its full-year forecast for profit attributable to owners of parent, reflecting the higher-than-initially-forecasted gain on sale of non-current assets, along with gain on sale of shares of subsidiaries and associates in third quarter.

Both transactions are aligned with the key initiative under H.U. 2030: "Optimizing capital allocation and improving capital efficiency." As a result, the Company expects its ROE for the fiscal year ending March 2026 to increase from the initial forecast of 4.1% to 5.2%. The Company will continue to implement the initiatives outlined in H.U. 2030, driving transformation toward a highly profitable structure while further enhancing capital efficiency.

The earnings forecasts above have been prepared based on information available as of the date on which this material was announced. Actual results may differ due to a variety of factors going forward.

End